NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Spine BioPharma, Inc.

Spine BioPharma, Inc.

Private
New York City, New YorkHealthcare & Life Scienceshttps://spinebiopharma.com

Last Round

Seed Round

Jun 5, 2026

Est. Valuation

$62.4M

Total Funding Raised

$17.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Spine BioPharma, Inc. is a biopharmaceutical company that develops non-surgical, non-opiate therapies for degenerative spine-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B2C

Customer Profile

Hardware Sales, Revenue Share

AI Layer

Non-AI

Keywords

degenerative disc diseasechronic low back painnon-surgical spine treatmentnon-opioid pain reliefvicatertideclinical stage biotechintradiscal injectionDDDspinal surgery alternativepeptide therapeuticTGF-β antagonistphase 3 clinical trialdrug developmentsingle-asset biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Spine BioPharma, Inc. Comparables

Compare Spine BioPharma, Inc. with similar companies based on industry and business-model similarity.

Spine BioPharma, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DiscGenics
85%
Notogen Inc.
80%
Stayble Therapeutics AB
79%

Spine BioPharma, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJun 5, 2026
Early FundingDec 18, 2024
Series BMar 24, 2022
Convertible DebtApr 20, 2021
Series AApr 1, 2021

Key People

Founding team and executive leadership

Marc Viscogliosi

Chairman CEO

Executive Team

Jason Gallagher

Chief Operating Officer & Chief Commercial Officer

Executive Team

Spine BioPharma, Inc. Investors

Notable investors and investment history

Spine BioPharma, Inc. investors
InvestorRounds
Cercano ManagementSeries A
Cercano ManagementSeries B
Viscogliosi Brothers, LLCSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 5, 2026

    $385K raised in Seed Round.

  • Apr 17, 2026

    Monthly visitors increased 146% MoM, reaching 5.3K.

Spine BioPharma, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Spine BioPharma, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Spine BioPharma, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range10
Year Founded2015
Last FundingJun 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.